OT-101

DRUG3 trials

Sponsors

Oncotelic Inc.

Conditions

COVID-19Malignant Pleural MesotheliomaPancreatic Ductal Adenocarcinoma

Phase 2

A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects

Oncotelic Inc.COVID-19

Start: 2021-04-30End: 2021-10-31Target: 18Updated: 2021-03-16

OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition

Not yet recruitingNCT05425576

Oncotelic Inc.Malignant Pleural Mesothelioma

Start: 2025-06-30End: 2029-12-31Target: 63Updated: 2024-03-15

A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer

RecruitingNCT06079346

Oncotelic Inc.Pancreatic Ductal Adenocarcinoma

Start: 2024-05-01End: 2027-06-01Target: 455Updated: 2024-08-13